Journal Logo

Articles by H. Einsele

EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY: S825

Topp, M.; Duell, J.; Zugmaier, G.; More

HemaSphere. 3:365, June 2019.

HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA: PS1001

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3:450, June 2019.

QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION: PS1509

Ludwig, H.; Pönisch, W.; Knop, S.; More

HemaSphere. 3:695-696, June 2019.